1.56
-0.04(-2.50%)
Currency In USD
Address
2223 Avenida de la Playa
LA Jolla, CA 92037
United States of America
Phone
619 400 1170
Website
Sector
Healthcare
Industry
Biotechnology
Employees
3
First IPO Date
February 10, 2021
| Name | Title | Pay | Year Born |
| Dr. W. Marc Hertz Ph.D. | Co-Founder, Chief Executive Officer, President & Director | 617,224 | 1971 |
| Dr. Vipin Kumar Chaturvedi Ph.D. | Co-Founder & Chief Scientific Officer | 419,420 | 1960 |
| Dr. Albert Agro Ph.d. | Co-Founder & Chief Medical Officer | 461,099 | 1965 |
| Ms. Leanne M. Kelly | Chief Financial Officer & Corporate Secretary | 469,420 | 1977 |
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
